Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
1 clinical trials · Condition
◉ Watch Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations (NCT01522469) | Arog Pharmaceuticals, Inc. | 2012-07-01 |
Track Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations automatically
Every clearance here is in the API, with alerts when new ones post.